var data={"title":"Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243657?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information&quot;</a> and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249383\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Miltefosine may cause fetal harm. Fetal death and teratogenicity occurred in animals administered miltefosine at doses lower than the recommended human dose. Do not administer miltefosine to pregnant women. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing miltefosine. Advise females of reproductive potential to use effective contraception during therapy and for 5 months after therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502570\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Impavido</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046437\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiparasitic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046440\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV positive/-exposed: Children &ge;12 years and Adolescents weighing &ge;30 kg: Oral: Cutaneous, mucosal, visceral leishmaniasis: <b>Note:</b> Efficacy is species- and locale-dependent. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">30 to 44 kg: 50 mg twice daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;45 kg: 50 mg 3 times daily 28 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV positive/-exposed: Adolescents: Oral: Visceral, initial acute infection: 100 mg daily for 28 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Naegleria fowleri</i> infection (free-living ameba):</b> Very limited data available; efficacy results variable; <b>Note:</b> Due to the poor prognosis of infection and lack of successful treatment options, expert recommendations suggest adding miltefosine as a component of treatment regimen and contacting CDC for procurement (CDC 2013; Cope 2016; Linam 2015; <i>Red Book</i> [AAP 2015]): Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;45 kg: 50 mg twice daily for 28 days; not to exceed 2.5 mg/kg/dose (Linam 2015); an 8-year-old (weight not reported) received 50 mg 3 times daily (Cope 2016)  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;45 kg: 50 mg 3 times daily for 28 days (Cope 2016; Linam 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Leishmaniasis:</b>  Non-HIV-1 positive patients: Cutaneous, mucosal, visceral: <b>Note:</b> Efficacy is species- and locale-dependent: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">30 to 44 kg: 50 mg twice daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;45 kg: 50 mg 3 times daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22904239\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Impavido: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502569\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815381\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">For the treatment of free-living amebae (FLA) infections, including primary amebic meningoencephalitis (PAM) caused by <i>Naegleria fowleri</i>, granulomatous amebic encephalitis caused by <i>Balamuthia mandrillaris</i>, and <i>Acanthamoeba</i> spp, miltefosine remains available from the CDC through an expanded access investigational new drug protocol (IND) with the FDA. Clinicians who suspect a FLA infection should contact the Centers for Disease Control (CDC) Emergency Operations Center at 770-488-7100 (24 hours/day, 7 days/week).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903463\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Free-living amebae infections:</b> Miltefosine is available in the US directly from the CDC through an expanded access investigational new drug protocol (IND) with the FDA for the treatment of free-living amebae (FLA) infections, including primary amebic meningoencephalitis (PAM) caused by <i>Naegleria fowleri</i>, granulomatous amebic encephalitis caused by <i>Balamuthia mandrillaris</i>, and <i>Acanthamoeba</i> spp. Clinicians who suspect an FLA infection should contact the Centers for Disease Control (CDC) Emergency Operations Center at 770-488-7100 (24 hours/day, 7 days/week). A CDC expert can offer assistance with diagnosis, specimen collection, shipping instructions, and treatment recommendations. Further information is available at <a target=\"_blank\" href=\"http://www.cdc.gov/parasites/naegleria/treatment.html&amp;token=2qlk56F/3K1cx+ynYS5+4qjjQ8xpG0RJ0thFmN+IkBU09Eb11Miii6qNe2tCpWRkLBkuQpgjRnQ0O50WGHZmQw==&amp;TOPIC_ID=109303\" target=\"_blank\">http://www.cdc.gov/parasites/naegleria/treatment.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24151847\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Impavido: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM390972.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WHeLlvW27hVqpt29VHRKVRA==&amp;TOPIC_ID=109303\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM390972.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046441\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Oral: Administer with food to decrease GI distress. Twice-daily dosing should be administered with breakfast and dinner; 3-times daily dosing with breakfast, lunch, and dinner. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24251363\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from moisture. Dispense in original carton.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046438\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of visceral leishmaniasis (caused by <i>Leishmania donovani</i>), cutaneous leishmaniasis (caused by <i>L. braziliensis</i>, <i>L. guyanensis</i>, and <i>L. panamensis</i>), and mucosal leishmaniasis (caused by <i>L. braziliensis</i>) (FDA approved in ages &ge;12 years weighing at least 30 kg and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22906300\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, fatigue, headache, malaise, paresthesia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Cellulitis, pruritus, pyoderma, skin rash, Stevens-Johnson syndrome, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, constipation, decreased appetite, diarrhea, dysphagia, flatulence, motion sickness, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Testicular pain, testicular swelling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, decreased platelet count, lymphadenopathy, lymphangitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess, ecthyma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine (&ge;1.5 times above baseline)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, decreased ejaculate volume, dry ejaculation, edema, epistaxis, increased serum bilirubin, jaundice, melena, peripheral edema, scrotal pain, seizure, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903471\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to miltefosine or any component of the formulation; Sjogren-Larsson syndrome; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903472\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Stevens-Johnson syndrome has been reported; discontinue miltefosine if an exfoliative or bullous rash occurs during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility effects: Miltefosine impaired female and male fertility in animals; effects on human fertility have not been adequately studied. Scrotal pain and decreased or absent ejaculation have been reported during miltefosine therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Nausea, vomiting and diarrhea may occur with use; administer with food to decrease GI effects. Ensure adequate fluid intake during therapy to prevent dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: Thrombocytopenia has been reported during therapy for visceral leishmaniasis; monitor platelet count during therapy in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increased liver transaminases and bilirubin have been reported during therapy for visceral leishmaniasis. Assess ALT, AST, and bilirubin during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May increase serum creatinine. Assess kidney function weekly while on therapy and for 4 weeks after the end of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Pregnancy: [US Boxed Warning]: Miltefosine may cause fetal harm; do not administer to pregnant women. Fetal death and teratogenicity occurred in animals at doses lower than the maximum recommended human dose. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing miltefosine. Females of reproductive potential should use effective contraception during miltefosine therapy and for 5 months thereafter;</b> if oral contraceptives are used and nausea, vomiting, and/or diarrhea occur during therapy, additional nonhormonal or alternative methods of effective contraception should be used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23358804\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23358801\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109303&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249400\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249401\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Miltefosine may cause fetal harm; do not administer to pregnant women. Fetal death and teratogenicity occurred in animals at doses lower than the maximum recommended human dose. A pregnancy test (serum or urine) should be obtained in females of reproductive potential prior to prescribing miltefosine. Females of reproductive potential should use effective contraception during therapy and for 5 months after therapy;</b> if oral contraceptives are used and nausea, vomiting, and/or diarrhea occur during therapy, additional nonhormonal or alternative methods of effective contraception should be used.  Untreated  visceral leishmaniasis may be life-threatening to the mother and may result in adverse fetal outcomes (eg, spontaneous abortion, congenital disease due to vertical transmission, small for gestational age newborn, severe anemia); untreated cutaneous leishmaniasis may manifest with larger and atypical appearing lesions and may be associated with adverse fetal outcomes (eg, preterm births, stillbirths). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046442\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Liver function tests (AST, ALT, alkaline phosphatase, bilirubin) and BUN/serum creatinine; platelet count </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903474\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Exact mechanism unknown; likely interaction with phospholipids and steroids in parasitic cell membranes, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903476\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; phospholipase D-like cleavage of miltefosine releases choline. Fatty alcohol-containing fragment may be oxidized to palmitic acid and undergo fatty acid metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absolute bioavailability in humans not studied</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: t<sup>1</sup>/<sub>2</sub> alpha: &gt;6 days; t<sup>1</sup>/<sub>2</sub> beta: ~31 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 4 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;0.2% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46817110\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Impavido Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (28): $19,200.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671518\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Impavido (BD, BR, CO, DE, EC, IL, IN, PY);</li>\n      <li>Miltex (AT, BE, BG, BR, CL, CZ, DE, DK, EE, FI, FR, GB, GR, HU, IL, IT, LT, LV, MY, SE, SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp infection with miltefosine. <i>Emerg Infect Dis</i>. 2008;14:1743-1746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/18976559/pubmed\" target=\"_blank\" id=\"18976559\">18976559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). <i>Naegleria fowleri</i> &ndash; Primary Amebic Meningoencephalitis (PAM). Available at: <a href=\"http://www.cdc.gov/parasites/naegleria/treatment-hcp.html\" target=\"_blank\">http://www.cdc.gov/parasites/naegleria/treatment-hcp.html</a>. Accessed November 13, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Leishmaniasis- Resources for Health Professionals. Available at: <a href=\"http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl\" target=\"_blank\">http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl</a>. Updated March 20, 2014. Accessed April 4, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cope JR, Conrad DA, Cohen N, et al. Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis: report of 1 fatal and 1 surviving case. <i>Clin Infect Dis</i>. 2016;62(6):774-776. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/26679626 /pubmed\" target=\"_blank\" id=\"26679626 \">26679626 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. May 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed July 4, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dorlo TP, Huitema ADR, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. <i>Antimicrob Agents Chemother</i>. 2012;56(7):3864-3872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/22585212/pubmed\" target=\"_blank\" id=\"22585212\">22585212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Impavido (miltefosine) [prescribing information]. Wilmington, DE: Paladin Therapeutics Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linam WM, Ahmed M, Cope JR, et al. Successful treatment of an adolescent with <i>Naegleria fowleri</i> primary amebic meningoencephalitis. <i>Pediatrics</i>. 2015;135(3):e744-748. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/25667249 /pubmed\" target=\"_blank\" id=\"25667249 \">25667249 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute;nez DY, Seas C, Bravo F, Legua P, Ramos C, Cabello AM, Gotuzzo E. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. <i>Clin Infect Dis</i>. 2010;51(2):e7-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/20550438/pubmed\" target=\"_blank\" id=\"20550438\">20550438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soto J, Arana A, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. <i>Clin Infect Dis</i>. 2004;38(9):1266-1272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/15127339/pubmed\" target=\"_blank\" id=\"15127339\">15127339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. <i>N Engl J Med</i>. 2002;347(22):1739-1746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/12456849/pubmed\" target=\"_blank\" id=\"12456849\">12456849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webster D, Umar I, Kolyvas G, et al. Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. <i>Am J Trop Med Hyg</i>. 2012;87(4):715-718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/22869634/pubmed\" target=\"_blank\" id=\"22869634\">22869634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO).  Application for inclusion of miltefosine on WHO model list of essential medicines (Paladin Pharmaceuticals).  November, 2010. http://www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf. Accessed April 4, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO).  WHO model list of essential medicines for adults, 18th edition, final amendments, October, 2013. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed April 4, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO).  WHO model list of essential medicines for children, 4th edition, final amendments, October, 2013.  Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed April 4, 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109303 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F24249383\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46502570\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F29046437\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F29046440\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F22904239\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F46502569\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F22815381\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F22903463\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F24151847\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F29046441\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F24251363\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F29046438\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22906300\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22903471\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22903472\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23358804\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23358801\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F24249400\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F24249401\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F29046442\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22903474\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F22903476\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46817110\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671518\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/109303|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</a></li><li><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}